Former bioMérieux production manager, Sébastien Quesney, will lead development and production of Magnetic Immunoassay (MIA)

Paris October 4, 2007 - Magnisense, a developer of next generation bioassays for human and animal diagnostics, food safety and environmental protection, announces today the appointment of Sébastien Quesney, PhD, as Technical Development Manager with worldwide responsibilities. The appointment reinforces Magnisense's management team, which now has the full range of skills to move Magnisense from being a start-up to a fully-fledged company with real products.

Quesney will be in charge of the development and production of Magnisense's MIAtek(TM) technology and will work with Magnisense's internal marketing and instrumentation teams and external partners involved in clinical trials or engineering.

Magnisense's innovative approach to bioassays using superparamagnetic beads as markers allows companies that have acquired the manufacturing license to benefit from the accuracy of laboratory testing as well as the ease of use of rapid point-of-care testing. The company has already brought two applications through to proof of feasibility. These are MIAstrip(TM) a single dose point-of-care test, and MIAflo(TM), a disposable cartridge for detection of bacterial contamination.

"Bringing Sébastien Quesney on board is a further sign of Magnisense's development as a company," said Luc Lenglet, President of Magnisense. "His experience in the diagnostics industry will allow us to ramp up our efforts to bring MIAtek(TM) technology to as many of those involved in diagnostics as possible."

Sébastien Quesney, 35, comes from bioMérieux where he was in charge of production and manufacturing of biological reagents. Before this, he headed up a research project at Sanofi and also worked on several projects at GBPDN, a research group in Rouen focused on biochemicals and digestive and nutritional physiopathology. He has a Masters in cellular biology from the University of Saint-Aignan in Rouen and a doctorate in life sciences from the Claude Bernard University in Lyon.

"Magnisense's magnetism-based approach revolutionizes immunoassays," said Quesney. "The development and production of the technology is an exciting task and I am looking forward to seeing it through with the rest of the Magnisense team."

About Magnisense http://www.magnisense.com
Magnisense develops next generation bioassays for human and animal diagnostics, food safety and environmental protection. These innovative immunoassays are based on superparamagnetic bead markers, which deliver the accuracy of laboratory testing with the ease of use of rapid test methods.

Exploiting a unique feature of superparamagnetic bead markers, Magnisense's MIAtek(TM) technology provides true quantification of a large volume sample. The magnetic signal is free of interference from environmental factors, permitting a more sensitive and reproducible detection than possible with other surface-restricted approaches.

Magnisense is developing two test formats for different application areas:
MIAstrip(TM): Point of care testing with a single dose, producing objective, quantifiable and traceable results via a portable reader and offering markers for a number of diseases including avian flu, cardiac disease, tetanus, and bacterial, viral, parasitic or mycotic infections.
MIAflo(TM): Disposable cartridges for detection of bacterial contamination in food products, e.g. Listeria and Salmonella, or in water, e.g. Legionella, with a sensitivity that brings a significant reduction in testing time.

Founded in 2003, Magnisense has raised two rounds of financing for a total of EUR 6 million from Baring Vostok Capital Partners and private investors.

For further information, please contact:

Andrew Lloyd & Associates
Andrew Lloyd / Neil Hunter
Tel: +44 1273 675100
allo@ala.com  / neil@ala.com